<!– –> <!– Page Last Updated: 10/01/2013 –> Page Last Updated: 10/01/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: La FDA advierte del aumento del riesgo de muerte con antibiótico Tygacil intravenoso (tigeciclina) y aprueba nuevo Recuadro con advertencia
Esta actualización se hace a manera de seguimiento al Comunicado de la FDA sobre la seguridad del medicamento: Mayor riesgo de muerte con Tygacil (tigeciclina) en comparación con otros antibióticos usados para el tratamiento de infecciones similares emitido el 1º de septiembre del 2010 (información en inglés). Anuncio de seguridad El 27 de septiembre, 2013,…
FDA Drug Safety Communication: FDA warns of increased risk of death with IV antibacterial Tygacil (tigecycline) and approves new Boxed Warning
<!– –> <!– Page Last Updated: 09/27/2013 –> Page Last Updated: 09/27/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Comunicado de la FDA sobre la seguridad de los medicamentos: FDA requiere cambio de color de parches analgésicos Duragesic (fentanilo) para mayor seguridad y enfatiza que la exposición accidental a parches usados puede causar la muerte
<!– –> <!– Page Last Updated: 09/25/2013 –> Page Last Updated: 09/25/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: Boxed Warning and new recommendations to decrease risk of hepatitis B reactivation with the immune-suppressing and anti-cancer drugs Arzerra (ofatumumab) and Rituxan (rituximab)
<!– –> <!– Page Last Updated: 09/25/2013 –> Page Last Updated: 09/25/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Drug Name Review
<!– –> <!– Page Last Updated: 09/23/2013 –> Page Last Updated: 09/23/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA requiring color changes to Duragesic (fentanyl) pain patches to aid safety―emphasizing that accidental exposure to used patches can cause death
<!– –> <!– Page Last Updated: 09/23/2013 –> Page Last Updated: 09/23/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA investiga infección cerebral poco común en paciente que tomó Gilenya (fingolimod)
<!– –> <!– Page Last Updated: 09/03/2013 –> Page Last Updated: 09/03/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
FDA Drug Safety Communication: FDA investigating rare brain infection in patient taking Gilenya (fingolimod)
<!– –> <!– Page Last Updated: 08/29/2013 –> Page Last Updated: 08/29/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.
Communicating Benefit and Risk Information
<!– –> <!– Page Last Updated: 08/21/2013 –> Page Last Updated: 08/21/2013 <!– –> Note: If you need help accessing information in different file formats, see Instructions for Downloading Viewers and Players.